Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 with Cyclophosphamide in Advanced Solid Tumors
NCT03733587Phase 1Completed
- Sponsor
- Genexine
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efineptakin alfa in solid tumor, sponsored by Genexine. Primary endpoints: Incidence of Dose Limiting Toxicity at 28 days, Incidence and Characteristics of Adverse Events at 24 months and 1 more. Started Oct 2018; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03733587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733587.